

## Recce Pharmaceuticals Expands U.S. Government Collaborations with Second Cooperative Research and Development Agreement (CRADA) to Advance RECCE® 327 Gel for Burn Wounds

### Highlights:

- Recce signs CRADA with the U.S. Army Institute of Surgical Research (USAISR), the U.S. Army's leader in Combat Casualty Research and Burn Care.
- Study will be conducted to evaluate RECCE® 327 Gel (R327G) in reducing bioburden Burn Wounds using the USAISR Walker-Mason rat model
- Study to evaluate whether R327G can effectively reduce bioburden of Methicillin-Resistant *Staphylococcus aureus* and *Pseudomonas aeruginosa* – two clinically significant bacterial pathogens associated with burn wound infections
- Marks Recce's R327G potential for supporting practical field deployment as a hydrogel wound dressing, with potential broader clinical and post-operative application
- Builds on Recce's first CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), reinforcing recognition of the Company's collaboration with the U.S. Department of War (previously Department of Defense) in advancing next-generation anti-infectives

**Sydney Australia, 2 February 2026:** Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**), the Company developing a New Class of Synthetic Anti-Infectives, today announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR).

USAISR, a world leader in studying combat casualty research and burn care for the warfighter, will evaluate the Company's topical formulation, RECCE® 327 Gel (R327G), in their validated Walker-Mason rat model of burn wound infection. This model was developed to mimic battlefield injuries and study systemic responses to burns and subsequent infections.



**ASX: RCE, FSE: R9Q**

**Head Office:** Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T +61 (2) 9000 1907**

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T +61 (8) 9362 9860**

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

The study aim is to assess whether R327G can significantly reduce bacterial burden in infected burn wounds, specifically against Methicillin-Resistant *Staphylococcus aureus* (MRSA) (ATCC43300) and *Pseudomonas aeruginosa* (*P. aeruginosa*) (ATCC27853), two major pathogens frequently isolated from burn patients.

Burn wound infections remain one of the leading causes of mortality in burn patients and are clinically difficult to manage due to the growing challenge of antimicrobial resistance. There is an urgent need for new, broad-spectrum anti-infectives that can rapidly treat wound infections without contributing to resistance.

R327G, a broad-spectrum synthetic anti-infective is being developed as a next-generation amorphous gel wound dressing and will offer practical utility for frontline deployment in military field kits, as well as potential application in clinical settings and post-operative care.

**Chief Executive Officer James Graham said,** “We are proud to strengthen our relationship with the United States Army through the establishment of a CRADA with the USAISR. This new agreement, together with our existing collaboration with the United States Army Medical Research Institute of Infectious Diseases, and our recent CDMRP grant award, demonstrates the accelerating U.S. Government interest in R327 across multiple operational and therapeutic applications. We are thankful for the ability of R327G to be delivered as a hydrogel dressing, positions as a truly unique solution for combat wound care and broader military and civilian healthcare needs continues to show promise with the U.S. Government.”

## About RECCE® 327 Gel

R327G is a topical formulation of Recce's lead compound, RECCE® 327, designed to provide rapid, broad-spectrum anti-infective action against Gram-positive and Gram-negative bacteria, including multidrug-resistant superbugs. With no loss of efficacy upon repeated use and minimal risk of development of bacterial resistance, R327G represents a novel approach in burn wound and trauma infection management.

## About the US Army Institute of Surgical Research (USAISR)

USAISR, located at Joint Base San Antonio-Fort Sam Houston, Texas, is the U.S. Army's premier laboratory for combat casualty care research. Its mission includes advancing treatments to improve the survival and recovery of soldiers with severe trauma, burns, and wound infections. USAISR has pioneered the Walker-Mason rat model, a clinically relevant platform for evaluating burn wound infection and treatment interventions.

## Background

Antibiotic resistance is an increasing problem with serious health consequences for both military, veteran, and civilian populations. The U.S. Government has continued to prioritize clinical research partnerships with the private and public sector, to accelerate the development of new therapeutic compounds having broad-spectrum antibacterial activity.

This announcement has been approved for release by Recce Pharmaceuticals Board.



### Media and Investor Relations

#### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

#### Australia

Andrew Geddes  
Seed Media  
[andrew@seedmedia.com.au](mailto:andrew@seedmedia.com.au)

#### USA & Europe

Guillaume van Renterghem  
LifeSci Advisors  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

## About United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

Since 1969, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of War equipped to safely study highly hazardous viruses requiring maximum containment at Biosafety Level 4. Research conducted at USAMRIID leads to vaccines, drugs, diagnostics, and training programs that protect both Warfighters and civilians. The Institute's unique science and technology base serves not only to address current threats to our Armed Forces but is an essential element in the medical response to any future biological threats that may confront our nation. For more information, visit: <https://usamriid.health.mil/>.

The information contained in this press release does not necessarily reflect the position or the policy of the U.S. Government and no official endorsement should be inferred.



recce.com.au

ACN 124 849 065

### Media and Investor Relations

#### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

#### Australia

Andrew Geddes  
Seed Media  
[andrew@seedmedia.com.au](mailto:andrew@seedmedia.com.au)

#### USA & Europe

Guillaume van Renterghem  
LifeSci Advisors  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)